Member Login
  1. Stocks
    2. /
  2. Moderna, Inc. (NasdaqGS: MRNA)
    3. /

NasdaqGS:MRNA (Moderna, Inc.)

About MRNA

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Moderna, Inc. (NasdaqGS: MRNA) Latest News

    Investing Articles

    The Moderna share price: have I missed the boat?

    | Jon Smith

    After rallying over 300% in the past year, Jonathan Smith offers his opinion on whether the Moderna share price still…

    Read more »

    Investing Articles

    The AstraZeneca share price steadies: is this FTSE 100 stock a good investment?

    | Kirsteen Mackay

    The AstraZeneca share price is showing resilience in the face of disappointing vaccine publicity. This FTSE 100 stock has a…

    Read more »